Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., . . . Tannir, N. M. (2022). Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085-2097. https://doi.org/10.1002/cncr.34180
Citace podle Chicago (17th ed.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer 128, no. 11 (2022): 2085-2097. https://doi.org/10.1002/cncr.34180.
Citace podle MLA (9th ed.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer, vol. 128, no. 11, 2022, pp. 2085-2097, https://doi.org/10.1002/cncr.34180.